{"id":"https://openalex.org/W2020638064","doi":"https://doi.org/10.1111/j.1464-5491.2007.02191.x","title":"Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug\u2010na\u00efve patients with Type 2 diabetes","display_name":"Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug\u2010na\u00efve patients with Type 2 diabetes","alternate_titles":[],"publication_year":2007,"publication_date":"2007-05-17","ids":{"openalex":"https://openalex.org/W2020638064","doi":"https://doi.org/10.1111/j.1464-5491.2007.02191.x","mag":"2020638064","pmid":"https://pubmed.ncbi.nlm.nih.gov/17509069"},"language":"en","primary_location":{"id":"doi:10.1111/j.1464-5491.2007.02191.x","doi":"https://doi.org/10.1111/j.1464-5491.2007.02191.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1464-5491.2007.02191.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-5491.2007.02191.x","source":{"id":"https://openalex.org/S72944096","display_name":"Diabetic Medicine","issn_l":"0742-3071","issn":["0742-3071","1096-9136","1464-5491"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetic Medicine","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2020638064"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-5491.2007.02191.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007864342","display_name":"Anja Schweizer","orcid":"https://orcid.org/0000-0001-8787-3442","observed_orcids":["https://orcid.org/0000-0001-8787-3442"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"A. Schweizer","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland. anja.schweizer@novartis.com","Novartis Pharma AG, Basel, SWITZERLAND"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland. anja.schweizer@novartis.com","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, SWITZERLAND","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085624659","display_name":"A. Couturier","orcid":"https://orcid.org/0000-0003-0193-7324","observed_orcids":["https://orcid.org/0000-0003-0193-7324"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Couturier","raw_affiliation_strings":["East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"East Hanover, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066047147","display_name":"James Edward Foley","orcid":"https://orcid.org/0000-0001-6857-1158","observed_orcids":["https://orcid.org/0000-0001-6857-1158"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. E. Foley","raw_affiliation_strings":["East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"East Hanover, NJ, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5025969627","display_name":"Sylvie Dejager","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"S. Dejager","raw_affiliation_strings":["Novartis Pharma AG and Novartis Pharmaceuticals Corporation, Basel, Switzerland and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG and Novartis Pharmaceuticals Corporation, Basel, Switzerland and","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5007864342"],"corresponding_institution_ids":["https://openalex.org/I1283582996"],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":null,"fwci":25.4014,"has_fulltext":true,"cited_by_count":264,"citation_normalized_percentile":{"value":0.99726373,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"24","issue":"9","first_page":"955","last_page":"961"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vildagliptin","display_name":"vildagliptin","score":0.925000011920929},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9819999933242798},{"id":"https://openalex.org/keywords/hba1c-reduction","display_name":"HbA1c reduction","score":0.8550000190734863},{"id":"https://openalex.org/keywords/drug-naive-patients","display_name":"drug-naive patients","score":0.8190000057220459},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.7089999914169312},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.7960000038146973},{"id":"https://openalex.org/keywords/body-weight","display_name":"body weight","score":0.6389999985694885},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.968999981880188},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9240000247955322},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.8149999976158142},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.48500001430511475},{"id":"https://openalex.org/keywords/long-term-treatment-efficacy","display_name":"long-term treatment efficacy","score":0.460999995470047},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.46799999475479126},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.5740000009536743},{"id":"https://openalex.org/keywords/patient-preferences","display_name":"patient preferences","score":0.3070000112056732}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.964279055595398},{"id":"https://openalex.org/C2776453732","wikidata":"https://www.wikidata.org/wiki/Q421042","display_name":"Vildagliptin","level":4,"score":0.9412102699279785},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.9097486138343811},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6630018949508667},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5966528058052063},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5932751893997192},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5061783194541931},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4541867971420288},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.40453019738197327}],"mesh":[{"descriptor_ui":"D000077597","descriptor_name":"Vildagliptin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006113","descriptor_name":"United Kingdom","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015992","descriptor_name":"Body Mass Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1464-5491.2007.02191.x","doi":"https://doi.org/10.1111/j.1464-5491.2007.02191.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1464-5491.2007.02191.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-5491.2007.02191.x","source":{"id":"https://openalex.org/S72944096","display_name":"Diabetic Medicine","issn_l":"0742-3071","issn":["0742-3071","1096-9136","1464-5491"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetic Medicine","raw_type":"journal-article"},{"id":"pmid:17509069","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17509069","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetic medicine : a journal of the British Diabetic Association","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1111/j.1464-5491.2007.02191.x","doi":"https://doi.org/10.1111/j.1464-5491.2007.02191.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1464-5491.2007.02191.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1464-5491.2007.02191.x","source":{"id":"https://openalex.org/S72944096","display_name":"Diabetic Medicine","issn_l":"0742-3071","issn":["0742-3071","1096-9136","1464-5491"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetic Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2020638064.pdf","grobid_xml":"https://content.openalex.org/works/W2020638064.grobid-xml"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W1975588287","https://openalex.org/W1976567448","https://openalex.org/W1989976483","https://openalex.org/W1991565451","https://openalex.org/W2032322539","https://openalex.org/W2036167841","https://openalex.org/W2043121816","https://openalex.org/W2049222364","https://openalex.org/W2049323977","https://openalex.org/W2054649558","https://openalex.org/W2077149049","https://openalex.org/W2093303670","https://openalex.org/W2097112828","https://openalex.org/W2120467396","https://openalex.org/W2121776978","https://openalex.org/W2121970519","https://openalex.org/W2129514415","https://openalex.org/W2135175231","https://openalex.org/W2152978153","https://openalex.org/W2163498104","https://openalex.org/W2167621077","https://openalex.org/W2169735327","https://openalex.org/W2337243793","https://openalex.org/W2752336761"],"related_works":["https://openalex.org/W2089443047","https://openalex.org/W2117762041","https://openalex.org/W1982067008","https://openalex.org/W2103828712","https://openalex.org/W1991951001","https://openalex.org/W2109649769","https://openalex.org/W2107562831","https://openalex.org/W1973383046","https://openalex.org/W2137471483","https://openalex.org/W2124465362"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"evaluate":[2],"the":[3,87,96,107,158,214],"ability":[4],"of":[5,36,83,86,137,184,203,223,231],"vildagliptin":[6,40,119,140,162,197,268],"and":[7,73,95,126,170,198,226,267],"metformin":[8,48,74,127,146,215,266],"to":[9,50,143],"sustain":[10],"reductions":[11,112],"in":[12,19,57,172,194,213,236,246,255],"HbA(1c)":[13,61,64,78,88,111,247],"over":[14,68],"a":[15,206,219,252],"1-year":[16,101,159,253],"treatment":[17,38,102,160,254],"period":[18],"drug-na\u00efve":[20,58,256],"patients":[21,59,174,185,195,204,257],"with":[22,39,103,117,161,258,264],"Type":[23,259],"2":[24,27,260],"diabetes":[25],"(Type":[26],"DM).":[28],"METHODS:":[29],"Double-blind,":[30],"randomized,":[31],"multicentre,":[32],"active-controlled,":[33],"parallel-group":[34],"study":[35,108],"52-week":[37],"(100":[41],"mg":[42,52,139,145],"daily,":[43,53],"n":[44,54],"=":[45,55,62,168],"526)":[46],"or":[47],"(titrated":[49],"2000":[51],"254)":[56],"(baseline":[60],"7.5-11.0%).":[63],"was":[65,90,98,149,190,210,233,249,262],"measured":[66],"periodically":[67],"1":[69],"year.":[70],"RESULTS:":[71],"Vildagliptin":[72],"each":[75],"rapidly":[76],"decreased":[77,171],"from":[79,113],"an":[80,187],"equal":[81],"baseline":[82,114],"8.7%.":[84],"Most":[85],"reduction":[89],"attained":[91],"by":[92,218],"week":[93],"12,":[94],"efficacy":[97],"sustained":[99,250],"throughout":[100,251],"both":[104,118,237,265],"agents.":[105],"At":[106],"end,":[109],"significant":[110],"were":[115],"seen":[116,263],"(-1.0":[120],"+/-":[121,129,164,176],"0.1%,":[122,130],"P":[123,131,167,179],"<":[124,132,180],"0.001)":[125],"(-1.4":[128],"0.001);":[133],"however,":[134],"statistical":[135],"non-inferiority":[136],"50":[138],"twice":[141,147],"daily":[142,148],"1000":[144],"not":[150,155],"established.":[151],"Body":[152],"weight":[153],"did":[154],"change":[156],"during":[157],"(0.3":[163],"0.2":[165],"kg,":[166,178],"0.17)":[169],"metformin-treated":[173],"(-1.9":[175],"0.3":[177],"0.001).":[181],"The":[182,201,229],"proportion":[183,202],"experiencing":[186,205],"adverse":[188,208],"event":[189,209],"70.1":[191],"vs.":[192],"75.4%":[193],"receiving":[196],"metformin,":[199],"respectively.":[200],"gastrointestinal":[207],"twofold":[211],"higher":[212],"group,":[216],"driven":[217],"3-4-fold":[220],"greater":[221],"incidence":[222,230],"diarrhoea,":[224],"nausea":[225],"abdominal":[227],"pain.":[228],"hypoglycaemia":[232],"similarly":[234],"low":[235],"groups":[238],"(<":[239],"1%).":[240],"CONCLUSIONS:":[241],"A":[242],"clinically":[243],"meaningful":[244],"decrease":[245],"that":[248],"DM":[261],"monotherapy.":[269]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2020638064","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":12},{"year":2014,"cited_by_count":17},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":14}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
